2024
A randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol
Bold K, Sharma A, Haeny A, Gueorguieva R, Buta E, Baldassarri S, Lempert L, Krishnan-Sarin S, O’Malley S. A randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol. BMC Psychiatry 2024, 24: 201. PMID: 38475757, PMCID: PMC10935798, DOI: 10.1186/s12888-024-05619-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultCigarette SmokingElectronic Nicotine Delivery SystemsFlavoring AgentsHumansMentholRandomized Controlled Trials as TopicTobacco ControlTobacco ProductsUnited StatesConceptsSmoking menthol cigarettesE-cigarettesCigarette useReduce tobacco-related health disparitiesTobacco-related health disparitiesMenthol cigarettesRates of menthol cigarette useTobacco use statusMenthol cigarette useRandomized controlled trialsPublic health problemHealth disparitiesTobacco policiesFlavored e-cigarettesSmoke-freeMenthol flavorsMenthol policiesBlack adultsQuit smokingNon-Black participantsSmoking behaviorFollow-up visitHealth problemsSecondary outcomesE-cigarette products
2014
Predictors of Abstinence from Heavy Drinking During Treatment in COMBINE and External Validation in PREDICT
Gueorguieva R, Wu R, O'Connor PG, Weisner C, Fucito LM, Hoffmann S, Mann K, O'Malley SS. Predictors of Abstinence from Heavy Drinking During Treatment in COMBINE and External Validation in PREDICT. Alcohol Clinical And Experimental Research 2014, 38: 2647-2656. PMID: 25346505, PMCID: PMC4397985, DOI: 10.1111/acer.12541.Peer-Reviewed Original ResearchAcamprosateAge FactorsAlcohol AbstinenceAlcohol DeterrentsAlcohol DrinkingBehavior TherapyCombined Modality TherapyControlled Clinical Trials as TopicDecision TreesGamma-GlutamyltransferaseGermanyGoalsHumansLogistic ModelsMiddle AgedNaltrexonePredictive Value of TestsRandomized Controlled Trials as TopicReproducibility of ResultsTaurineTime FactorsTreatment OutcomeUnited States
2011
Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses
Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses. JAMA Psychiatry 2011, 68: 1227-1237. PMID: 22147842, PMCID: PMC3339151, DOI: 10.1001/archgenpsychiatry.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsData Interpretation, StatisticalDepressive Disorder, MajorDouble-Blind MethodDuloxetine HydrochlorideFemaleHumansLinear ModelsMalePatient DropoutsPlacebo EffectPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexThiophenesTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsPlacebo-treated patientsComparator selective serotonin reuptake inhibitorsHAM-D scoresClinical trialsAntidepressant treatmentPlacebo responseMajor depressionDouble-blind clinical trialHigh placebo response rateSerotonergic antidepressant treatmentPlacebo response ratesSerotonin reuptake inhibitorsAntidepressant nonrespondersPlacebo armMost patientsAntidepressant respondersMedication risksReuptake inhibitorsSerotonergic antidepressantsResponder statusTreatment responseClinical trajectoriesDepression scoresDepression severity
2007
New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials
Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O’Malley S, Krystal JH. New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. Biological Psychiatry 2007, 61: 1290-1295. PMID: 17224132, PMCID: PMC1952242, DOI: 10.1016/j.biopsych.2006.09.038.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAnalysis of VarianceData Interpretation, StatisticalDouble-Blind MethodFemaleHumansMaleNaltrexoneNarcotic AntagonistsOdds RatioRandomized Controlled Trials as TopicRetrospective StudiesSample SizeTreatment OutcomeConceptsNegative clinical trials
2005
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. JAMA Psychiatry 2005, 62: 961-970. PMID: 16143728, DOI: 10.1001/archpsyc.62.9.961.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntipsychotic AgentsBrief Psychiatric Rating ScaleDouble-Blind MethodDrug Administration ScheduleFemaleHumansMalePlacebosPsychotic DisordersRandomized Controlled Trials as TopicResearch DesignSchizophreniaSchizophrenic PsychologySelection BiasSeverity of Illness IndexSex FactorsTreatment OutcomeConceptsBrief Psychiatric Rating ScalePlacebo-controlled trialPsychiatric Rating ScalePlacebo-controlled studyAtypical antipsychotic medicationsDose-controlled studyMedication trialsAntipsychotic medicationRating ScaleDouble-blind clinical trialNew atypical antipsychotic medicationsDose-controlled trialsTreatment completion ratesPlacebo control groupEnd point changePercentage of menDrug Administration databaseRandom effects analysisIll adultsMedication armClinical trialsNew medicationsNovel medicationsSame drugAverage age